Key result
HFpEF in systemic sclerosis carries no independent mortality risk after age adjustment.
Why the study?
Heart failure with preserved ejection fraction is a clinically relevant complication of systemic sclerosis, but its prevalence, correlates, and prognostic significance needed examination.
Does the presence of HFpEF predict mortality in patients with systemic sclerosis?
Cohort (n=155)
Does the presence of HFpEF predict mortality in patients with systemic sclerosis?
In patients with systemic sclerosis, HFpEF is common (27%) and associated with increased mortality, though this association is largely driven by older age, whereas NT-proBNP independently predicts worse prognosis.
HFpEF-mortality link in systemic sclerosis is age-dependent; hypothesis-generating for NT-proBNP as independent prognostic marker.
Aim: Heart failure with preserved ejection fraction (HFpEF) is a clinically relevant complication of systemic sclerosis (SSc). We aimed to examine the prevalence, correlates and prognostic significance of HFpEF in an SSc population. Materials & methods: HFpEF was defined by the presence of exertional dyspnoea, abnormal cardiac structure (left ventricular hypertrophy or left atrial enlargement) and NT-proBN (>125 pg/ml). Results: Of the 155 studied patients, 27% had HFpEF criteria. These patients were older, had more cardiovascular risk factors, and were more likely to have atrial fibrillation or interstitial lung disease. Conclusion: Over a median follow-up of 9 years, SSc patients with HFpEF had a 3.4-fold increased risk of dying (HR: 3.37, 95% CI: 1.21–9.31), although this association has lost statistical significance after adjusting for age. On the contrary, NT-proBNP was an independent predictor of a worse prognosis.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2021) conducted a cohort in Systemic sclerosis (n=155). Heart failure with preserved ejection fraction (HFpEF) vs. Without HFpEF was evaluated on Risk of dying (HR 3.37, 95% CI 1.21-9.31). Systemic sclerosis patients with HFpEF had a 3.4-fold increased risk of dying (HR 3.37; 95% CI 1.21-9.31) over 9 years, though this association lost statistical significance after adjusting for age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: